<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dermatoses of pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dermatoses of pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dermatoses of pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Miriam Keltz Pomeranz, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The dermatoses of pregnancy are a heterogeneous group of pruritic inflammatory dermatoses that occur exclusively during pregnancy and/or in the immediate postpartum period [<a href="#rid1">1</a>]. These include the following conditions, which are discussed below [<a href="#rid2">2-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pemphigoid gestationis</p><p class="bulletIndent1"><span class="glyph">●</span>Polymorphic eruption of pregnancy (pruritic urticarial papules and plaques of pregnancy [PUPPP])</p><p class="bulletIndent1"><span class="glyph">●</span>Atopic eruption of pregnancy (eczema in pregnancy, prurigo of pregnancy, pruritic folliculitis of pregnancy)</p><p class="bulletIndent1"><span class="glyph">●</span>Intrahepatic cholestasis of pregnancy (see  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pustular psoriasis of pregnancy</p><p></p><p>Normal physiologic changes of the maternal skin and appendages during pregnancy are reviewed elsewhere  (<a class="graphic graphic_table graphicRef78973" href="/z/d/graphic/78973.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/456.html" rel="external">"Maternal adaptations to pregnancy: Skin and related structures"</a>.)</p><p>Dermatoses occurring in the nonpregnant population that may flare or remit during pregnancy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5663.html" rel="external">"Management of psoriasis in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p class="headingAnchor" id="H1209229753"><span class="h1">EVALUATION OF THE PREGNANT INDIVIDUAL WITH A PRURITIC ERUPTION</span><span class="headingEndMark"> — </span>Pruritus during pregnancy is a major symptom of specific dermatoses of pregnancy, although it may also be physiologic (idiopathic pruritus or pruritus gravidarum) or associated with common inflammatory skin diseases, infections, or infestations (eg, allergic contact dermatitis, pityriasis rosea, scabies) occurring coincidentally during pregnancy. Severe generalized pruritus, especially if predominant on the palms and soles, in the absence of primary skin lesions suggests intrahepatic cholestasis of pregnancy (ICP). (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a>.)</p><p>A new pruritic skin eruption that occurs during pregnancy requires immediate evaluation and diagnosis in consultation with a dermatologist because delayed diagnosis or misdiagnosis may pose a significant risk to the fetus (preterm delivery, small for gestational age) and the mother [<a href="#rid7">7</a>]. The initial assessment involves  (<a class="graphic graphic_table graphicRef69237" href="/z/d/graphic/69237.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong> – Obtaining a detailed medical history, including personal and family history of atopy, obstetric history (primigravida, multiple gestation pregnancy, similar illness in previous pregnancies), and time of onset of the current eruption (early or late pregnancy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin examination</strong> – Total body skin examination for type and distribution of lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin biopsy</strong> – Skin biopsy for histopathologic examination and direct immunofluorescence (DIF) staining if the diagnosis is uncertain and pemphigoid gestationis is suspected. A skin biopsy should also be performed to confirm a clinical diagnosis of pustular psoriasis of pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> – Laboratory testing (eg, total serum bile acids, metabolic panel, circulating antibodies against the bullous pemphigoid antigen 180) is indicated based upon the clinical findings  (<a class="graphic graphic_table graphicRef110440" href="/z/d/graphic/110440.html" rel="external">table 3</a>) if there is clinical suspicion of a dermatosis associated with fetal and maternal risk, such as pemphigoid gestationis, ICP, and generalized pustular psoriasis.</p><p></p><p class="headingAnchor" id="H2659415093"><span class="h1">WHEN TO SUSPECT A SPECIFIC DERMATOSIS OF PREGNANCY</span><span class="headingEndMark"> — </span>In a pregnant individual presenting with rash and pruritus, a specific dermatosis of pregnancy can be suspected based on history and clinical features, including time of onset and type and distribution of lesions  (<a class="graphic graphic_table graphicRef110440" href="/z/d/graphic/110440.html" rel="external">table 3</a>). In particular:</p><p class="bulletIndent1"><span class="glyph">●</span>Eczematous lesions with a flexural distribution suggest atopic eruption of pregnancy (AEP)  (<a class="graphic graphic_picture graphicRef57982" href="/z/d/graphic/57982.html" rel="external">picture 1A</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular lesions on the limbs suggest prurigo-type AEP  (<a class="graphic graphic_picture graphicRef72147" href="/z/d/graphic/72147.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of striae is common in polymorphic eruption of pregnancy (PEP)  (<a class="graphic graphic_picture graphicRef81605" href="/z/d/graphic/81605.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urticarial lesions are most common with PEP or pemphigoid gestationis, which also can display vesicular lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythematous plaques with sterile pustules at the periphery starting at flexural areas suggest pustular psoriasis of pregnancy (PPP)  (<a class="graphic graphic_picture graphicRef110694" href="/z/d/graphic/110694.html" rel="external">picture 4</a>).</p><p></p><p>Any patient with lesions suggesting pemphigoid gestationis or PPP should be referred to a dermatologist for evaluation and diagnosis.</p><p class="headingAnchor" id="H2596115468"><span class="h1">ATOPIC ERUPTION OF PREGNANCY</span><span class="headingEndMark"> — </span>Atopic eruption of pregnancy (AEP) is a pruritic disorder of pregnancy that presents as an eczematous or papular eruption in patients with an atopic background. It starts during early pregnancy, with 75 percent of cases occurring before the third trimester, and tends to recur in subsequent pregnancies.</p><p>"Atopic eruption of pregnancy" is a unifying term that includes eczema in pregnancy, prurigo of pregnancy (also called prurigo gestationis of Besnier, Nurse's early-onset prurigo of pregnancy, Spangler's papular dermatitis of pregnancy, and linear immunoglobulin M [IgM] disease of pregnancy), and pruritic folliculitis of pregnancy, which were previously considered distinct entities [<a href="#rid3">3</a>]. This classification scheme is based upon the presence of shared clinical features, including a possible association with atopy. However, not all experts agree that pruritic folliculitis of pregnancy and prurigo of pregnancy are best "lumped" within a disorder of atopic diathesis [<a href="#rid8">8</a>].</p><p>None of the disorders classified within this group are associated with adverse effects on the fetus [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H952357374"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>AEP is the most common of the pregnancy dermatoses, accounting for over 50 percent of all cases [<a href="#rid3">3</a>]. Its precise incidence is unknown. AEP is associated with a personal or family history of atopy (seasonal rhinitis, asthma, and/or atopic dermatitis) and is the first manifestation of atopic skin changes in most cases [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H3668416506"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>AEP is thought to be triggered by immunologic changes associated with pregnancy. It is postulated that reduced production of T helper type 1 (Th1) cytokines and enhancement of T helper type 2 (Th2) cytokine production, which is known to occur during pregnancy, may contribute to the development of eczema [<a href="#rid3">3,9</a>]. A relationship with a history of atopy has been proposed but remains controversial [<a href="#rid2">2,3,10</a>].</p><p class="headingAnchor" id="H1638994787"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>AEP often begins during the first or second trimester and is in most cases the first manifestation of atopic skin changes or, in patients with a history of atopic dermatitis, the recurrence of atopic dermatitis after years of remission [<a href="#rid2">2,11</a>]. In approximately 20 percent of cases, AEP represents an exacerbation of a pre-existing atopic dermatitis.</p><p class="headingAnchor" id="H403959094"><span class="h3">Eczema</span><span class="headingEndMark"> — </span>The vast majority of patients with AEP present with a widespread, eczematous eruption (the E-type AEP) involving the face, neck, and flexural areas, similar to classic atopic dermatitis  (<a class="graphic graphic_picture graphicRef57982 graphicRef68215" href="/z/d/graphic/57982.html" rel="external">picture 1A-B</a>) [<a href="#rid3">3</a>]. However, any area of the skin may be affected. Lesions may be eczematous patches or intact or excoriated papules. Papules can be follicle based, grouped, or scattered  (<a class="graphic graphic_picture graphicRef55424" href="/z/d/graphic/55424.html" rel="external">picture 5</a>). Skin dryness, which may be severe, is invariably present.</p><p class="headingAnchor" id="H3214132719"><span class="h3">Prurigo of pregnancy</span><span class="headingEndMark"> — </span>A less common presentation of AEP is prurigo of pregnancy, also called P-type AEP, which presents with erythematous, excoriated nodules or papules on the extensor surfaces of the limbs and trunk  (<a class="graphic graphic_picture graphicRef72147" href="/z/d/graphic/72147.html" rel="external">picture 2</a>) [<a href="#rid2">2,10-12</a>]. Lesions are grouped and may be crusted or appear eczematous. In one series, all 12 patients had abdominal involvement, with some also having the legs, wrists, and hands affected [<a href="#rid2">2</a>]. The eruption usually resolves in the immediate postpartum period [<a href="#rid2">2</a>], although it can persist for up to three months [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H2318136931"><span class="h3">Pruritic folliculitis of pregnancy</span><span class="headingEndMark"> — </span>In rare cases, AEP presents as a follicular, papulopustular eruption (formerly known as pruritic folliculitis of pregnancy). Scattered, follicle-based papules and pustules initially appear on the abdomen but may spread to the trunk and extremities and become generalized [<a href="#rid2">2,8,14</a>]. The appearance is similar to that of steroid-induced acne and is only mildly pruritic [<a href="#rid8">8</a>].</p><p>The eruption typically clears within two weeks of delivery [<a href="#rid15">15,16</a>]. However, one report described a case with persistent symptoms for six weeks postpartum [<a href="#rid14">14</a>], and another series noted that all 14 of the cases resolved prior to delivery [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2535149689"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis is usually clinical, based upon the recognition of clinical features in a patient with a personal or family history of atopy. A skin biopsy is not generally helpful, as the findings are nonspecific. However, a biopsy should be performed if there is diagnostic uncertainty or there is suspicion of pemphigoid gestationis. (See <a class="local">'Pemphigoid gestationis'</a> below.)</p><p>Although laboratory testing is not generally indicated, up to 70 percent of patients may have elevated serum immunoglobulin E (IgE) levels [<a href="#rid3">3</a>]. In patients presenting with folliculitis, a pustule should be cultured to rule out bacterial or candidal folliculitis.</p><p class="headingAnchor" id="H2632886320"><span class="h3">Pathology</span><span class="headingEndMark"> — </span>Spongiosis and a perivascular mononuclear infiltrate are common features of eczematous eruptions [<a href="#rid2">2</a>]. Epidermal hyperkeratosis or parakeratosis may also be present. A dermal, perivascular, lymphocytic infiltrate without eosinophils can also be noted. The epidermis may show acanthosis, hyperkeratosis, and parakeratosis.</p><p>A follicle-centered, lymphohistiocytic infiltrate containing neutrophils, eosinophils, and plasma cells and neutrophilic pustules with histopathologic features of sterile folliculitis can be seen in the folliculitis-type AEP [<a href="#rid2">2,14,16</a>].</p><p>Direct immunofluorescence (DIF) and indirect immunofluorescence studies are negative.</p><p class="headingAnchor" id="H3489661175"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of AEP includes spongiotic dermatitides that are not specifically associated with pregnancy (eg, allergic contact dermatitis, pityriasis rosea, maculopapular drug eruption), polymorphic eruption of pregnancy (PEP), and early stage of pemphigoid gestationis.</p><p>Clinically, the eczema-type AEP can be differentiated from PEP and early pemphigoid gestationis by its earlier onset, predilection for involvement of skin flexures, and absence of urticarial plaques in abdominal striae. The clinical differentiation of prurigo-type AEP from PEP or early pemphigoid gestationis may be difficult. In these cases, a skin biopsy may be helpful for the correct diagnosis. Although prurigo-type AEP and PEP share several histopathologic features, the finding of lymphocytic vasculitis, eosinophils in the interstitial dermis, edema, and mucin deposition in the dermis suggest PEP rather than AEP [<a href="#rid6">6</a>]. (See <a class="local">'Pathology'</a> below.)</p><p>Secondary lesions of intrahepatic cholestasis of pregnancy (ICP) and eruptions not associated with pregnancy (eg, scabies, drug reactions) should be excluded by history and laboratory testing (eg, bile acids) as indicated [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3868623729"><span class="h2">Management</span><span class="headingEndMark"> — </span>The goal of treatment is relief of symptoms. Similar to nonpregnant patients with eczema, patients with AEP should be encouraged to maintain adequate skin hydration through the frequent use of emollients.</p><p>Low- to mid-potency topical corticosteroids (groups 4 to 6  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 4</a>)) are useful for controlling symptoms. Vehicles for topical corticosteroids and doses are illustrated in the tables  (<a class="graphic graphic_table graphicRef76586 graphicRef60921" href="/z/d/graphic/76586.html" rel="external">table 5A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p>First-generation oral antihistamine <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">chlorpheniramine</a> or second-generation <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a> and <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a> may be helpful for controlling pruritus. (See  <a class="medical medical_review" href="/z/d/html/5552.html" rel="external">"Recognition and management of allergic disease during pregnancy", section on 'Oral antihistamines'</a>.)</p><p class="headingAnchor" id="H2194032994"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>AEP has not been associated with adverse effects on the fetus [<a href="#rid2">2</a>]. AEP may recur with subsequent pregnancies [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H13"><span class="h1">POLYMORPHIC ERUPTION OF PREGNANCY</span><span class="headingEndMark"> — </span>Polymorphic eruption of pregnancy (PEP), also called pruritic urticarial papules and plaques of pregnancy (PUPPP), is a benign, self-limiting, pruritic, inflammatory disorder that usually affects primiparous women in the last few weeks of pregnancy or immediately postpartum [<a href="#rid17">17</a>]. Toxic erythema of pregnancy, Bourne's toxemic rash of pregnancy, linear IgM dermatosis of pregnancy, and Nurse's late-onset prurigo are older terms felt to represent this same entity [<a href="#rid11">11,15,18,19</a>].</p><p class="headingAnchor" id="H2571217470"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>PEP is relatively common, occurring in approximately 1 in 160 to 300 pregnancies [<a href="#rid11">11,15</a>]. Three-quarters of patients with the classic type of PEP are nulliparous [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H288092599"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The etiopathogenesis of PEP is unknown and may be heterogeneous [<a href="#rid11">11,18</a>]. The degree of stretching of the abdominal skin may play a role. PEP is more common with excessive stretching, especially in women with multiple gestation [<a href="#rid15">15,20-22</a>].</p><p>It has been hypothesized that stretching may cause damage to connective tissue, which results in exposure of dermal antigens that trigger an inflammatory response [<a href="#rid20">20,23</a>]. A role of reproductive hormones in the pathogenesis of PEP has not been demonstrated.</p><p>Another possibility is that PEP represents an immunologic response to circulating fetal antigens. As an example, one study demonstrated fetal male deoxyribonucleic acid (DNA) in maternal skin lesions, a possible result of blood chimerism (fetal cells detected in maternal blood throughout pregnancy) [<a href="#rid24">24</a>]. However, this hypothesis has not been confirmed, although several studies have reported a preponderance of male fetuses in women with PEP [<a href="#rid2">2,25,26</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>PEP usually occurs in nulliparous women late in the third trimester (mean onset 35 weeks) but may develop postpartum [<a href="#rid18">18,25,27</a>]. There are also rare case reports of first and second trimester disease [<a href="#rid18">18</a>].</p><p>PEP typically presents as extremely pruritic, erythematous papules within striae  (<a class="graphic graphic_picture graphicRef81605" href="/z/d/graphic/81605.html" rel="external">picture 3</a>). Abdominal striae are the most common initial site (with periumbilical sparing) and may be the only initial site [<a href="#rid25">25</a>]. The lesions then spread to the extremities, chest, and back and coalesce to form urticarial plaques  (<a class="graphic graphic_picture graphicRef56116 graphicRef75861" href="/z/d/graphic/56116.html" rel="external">picture 6A-B</a>) [<a href="#rid28">28</a>]. The face, palms, and soles are usually spared.</p><p>White halos often surround the erythematous papules in patients with fair skin  (<a class="graphic graphic_picture graphicRef68906" href="/z/d/graphic/68906.html" rel="external">picture 7</a>). Over the course of the disease, approximately one-half of the patients develop more polymorphic lesions, including target-like lesions exhibiting three distinct rings/color changes instead of a halo, or erythematous patches and vesicles [<a href="#rid10">10,17,18,28</a>].</p><p>The eruption generally lasts four to six weeks and resolves within two weeks postpartum, although it may last longer or resolve prior to delivery [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2077854605"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of PEP is usually clinical, based upon history and physical examination  (<a class="graphic graphic_table graphicRef110440" href="/z/d/graphic/110440.html" rel="external">table 3</a>). A skin biopsy is generally not necessary for diagnosis but may be performed in cases of diagnostic uncertainty. There are no laboratory abnormalities related to PEP [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Pathology</span><span class="headingEndMark"> — </span>Histopathologic examination of a skin biopsy reveals a perivascular (superficial and deep) and interstitial, lymphocytic infiltrate containing eosinophils [<a href="#rid6">6</a>]. Features of lymphocytic vasculitis may be seen in some cases. Epidermal changes, including mild epidermal hyperplasia, spongiosis, and parakeratosis, are seen in approximately 30 to 50 percent of cases [<a href="#rid6">6,28</a>]. Additional findings include dermal edema and focal deposition of mucin.</p><p>Immunohistochemical studies reveal a predominantly T helper lymphocytic infiltrate with an increased number of CD1a<sup>+</sup>, CD54<sup>+ </sup>(ICAM-1<sup>+</sup>) dendritic cells, and CD1a<sup>+</sup> epidermal Langerhans cells in lesional skin.</p><p>Direct immunofluorescence (DIF) is usually negative or may demonstrate a nonspecific deposition of C3 and IgM or immunoglobulin A (IgA) deposits at the dermoepidermal junction or around blood vessels in a minority of cases [<a href="#rid18">18</a>]. These deposits are granular, not linear, as in pemphigoid gestationis. Indirect immunofluorescence is always negative.</p><p class="headingAnchor" id="H20"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>PEP can mimic the early, urticarial phase of pemphigoid gestationis, although in contrast with pemphigoid gestationis, PEP typically spares the umbilical region  (<a class="graphic graphic_table graphicRef110440" href="/z/d/graphic/110440.html" rel="external">table 3</a>). In uncertain cases, the two disorders can be distinguished by DIF of a biopsy specimen. (See <a class="local">'Pemphigoid gestationis'</a> below.)</p><p>The target-like lesions of PEP may appear similar to erythema multiforme. Drug reactions, viral syndromes, and infestations (scabies) may also present with erythematous papules similar to PEP [<a href="#rid11">11,18</a>]. The clinical history, routine histology, and serology help in differentiating among these entities. (See  <a class="medical medical_review" href="/z/d/html/2089.html" rel="external">"Drug eruptions"</a> and  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The goal of treatment is relief of symptoms. We suggest mid- to high-potency topical corticosteroids (groups 2 to 4  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 4</a>)) as initial therapy for PEP. Topical corticosteroids can be applied once or twice daily until improvement occurs. The cumulative amounts of topical corticosteroids used for the treatment of specific body areas in adults are shown in the table  (<a class="graphic graphic_table graphicRef76586" href="/z/d/graphic/76586.html" rel="external">table 5A</a>). (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Use during pregnancy or lactation'</a>.)</p><p>The safety of topical corticosteroid use during pregnancy is supported by several observational studies and meta-analyses [<a href="#rid29">29,30</a>]. However, the use of potent or superpotent topical corticosteroids exceeding 300 g during the whole pregnancy may be associated with an increased risk of low birth weight [<a href="#rid31">31</a>].</p><p>In severe cases, a short course of systemic corticosteroids with a quick taper, such as <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> 0.5 mg/kg per day for one week, tapered over one to two weeks, may be given for rapid resolution of symptoms [<a href="#rid17">17</a>].</p><p><a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">Chlorpheniramine</a>, a first-generation oral antihistamine, or second-generation nonsedating oral antihistamines, such as <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a> and <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a>, may be helpful to control pruritus. (See  <a class="medical medical_review" href="/z/d/html/5552.html" rel="external">"Recognition and management of allergic disease during pregnancy", section on 'Oral antihistamines'</a>.)</p><p>Early delivery to end symptoms is rarely, if ever, necessary [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>PEP generally lasts four to six weeks and resolves within two weeks postpartum, although it may last longer. In one series, the process resolved prior to delivery in 6 of 15 patients [<a href="#rid10">10</a>].</p><p>PEP poses no increased risk of fetal or maternal morbidity (other than maternal pruritus) [<a href="#rid11">11,25</a>]. Recurrence is rare [<a href="#rid18">18,25</a>].</p><p class="headingAnchor" id="H232357055"><span class="h1">PEMPHIGOID GESTATIONIS</span><span class="headingEndMark"> — </span>Pemphigoid gestationis (formerly called herpes gestationis) is a rare autoimmune bullous disease that occurs during the second or third trimester of pregnancy and may be associated with increased fetal risk [<a href="#rid33">33</a>]. A review of 61 pregnancies complicated by pemphigoid gestationis reported 20 (34 percent) preterm births [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2316674062"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Pemphigoid gestationis is rare. Its incidence has been estimated at 1 in 20,000 to 50,000 pregnancies. It only occurs during pregnancy or, in a minority of cases, as a paraneoplastic manifestation in females with trophoblastic tumors [<a href="#rid10">10,11,34-36</a>].</p><p class="headingAnchor" id="H3529500198"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Pemphigoid gestationis is caused by circulating immunoglobulin G1 (IgG1) autoantibodies directed against the 180 kilodalton bullous pemphigoid antigen (BP180 or collagen XVII), a transmembrane hemidesmosomal glycoprotein expressed in the basement membrane zone of the skin. The majority of patient sera bind to the extracellular NC16A epitope, but some bind to other epitopes on BP180, both intracellular and extracellular [<a href="#rid37">37</a>].</p><p>As in bullous pemphigoid, the binding of antibodies to antigens within the basement membrane zone stimulates an inflammatory cascade that results in separation of the epidermis from the dermis [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Pathogenesis'</a>.)</p><p>In pemphigoid gestationis, the primary site of autoimmunity seems to be the placenta, as antibodies bind not only to the basement membrane zone of the epidermis, but also to that of chorionic and amniotic epithelia, both of ectodermal origin. It has been theorized that paternal major histocompatability complex (MHC) class II antigens found on the chorionic villi induce maternal antibodies to the amniotic basement membrane. These antibodies can then cross-react with skin and cause maternal (and sometimes newborn) disease [<a href="#rid39">39</a>].</p><p>The hypothesis of a genetic predisposition is supported by the observation of an association between pemphigoid gestationis and class II human leukocyte antigen (HLA) phenotype HLA-DR3/HLA-DR4 [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H178702062"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Pemphigoid gestationis presents most often in the second or third trimester of pregnancy. Intense pruritus may precede the onset of visible skin lesions. The rash typically begins on the trunk as urticarial plaques or papules surrounding the umbilicus  (<a class="graphic graphic_picture graphicRef78383 graphicRef63947 graphicRef72928" href="/z/d/graphic/78383.html" rel="external">picture 8A-C</a> and <a class="graphic graphic_table graphicRef110440" href="/z/d/graphic/110440.html" rel="external">table 3</a>) [<a href="#rid10">10,11,34</a>]. Vesicles may also be present  (<a class="graphic graphic_picture graphicRef65231" href="/z/d/graphic/65231.html" rel="external">picture 9</a>). Lesions may be seen on the palms and soles but rarely on the face or mucous membranes. The eruption spreads rapidly and forms tense blisters  (<a class="graphic graphic_picture graphicRef134253 graphicRef72690 graphicRef52776" href="/z/d/graphic/134253.html" rel="external">picture 10A-C</a>). The entire body surface may be involved, but the mucous membranes are usually spared.</p><p>Pemphigoid gestationis may remit prior to delivery. However, 75 percent of patients have a flare postpartum, and at least 25 percent of patients subsequently have a flare with use of oral contraceptive pills or during menses. Most cases spontaneously resolve in the weeks to months following delivery. The disease usually recurs with subsequent pregnancies and is often worse [<a href="#rid11">11</a>] but may also skip pregnancies [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2072618000"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of pemphigoid gestationis is based upon the combination of clinical findings  (<a class="graphic graphic_table graphicRef110440" href="/z/d/graphic/110440.html" rel="external">table 3</a>), examination of a lesional skin biopsy for routine histopathology and a perilesional skin biopsy for direct immunofluorescence (DIF), and measurement of serum levels of anti-BP180 antibodies by enzyme-linked immunosorbent assay (BP180 NC16A ELISA).</p><p class="headingAnchor" id="H2981954346"><span class="h3">Pathology</span><span class="headingEndMark"> — </span>Biopsy of a vesiculating lesion (using routine histologic processing) reveals a subepidermal vesicle with a perivascular lymphocytic and eosinophilic infiltrate. Eosinophils may appear at the dermoepidermal junction and filling the vesicle. Basal cell necrosis and edema of the dermal papillae are usually noted.</p><p class="headingAnchor" id="H3312113279"><span class="h3">Direct immunofluorescence</span><span class="headingEndMark"> — </span>Using a snap-frozen perilesional skin biopsy, DIF reveals a homogeneous, linear deposit of complement C3 at the basement membrane zone  (<a class="graphic graphic_picture graphicRef65548" href="/z/d/graphic/65548.html" rel="external">picture 11</a>). The presence of C3 is pathognomonic for pemphigoid gestationis in a pregnant patient. Immunoglobulin G (IgG) deposits are also present in 30 to 40 percent of patients but are not a criterion for diagnosis.</p><p class="headingAnchor" id="H1928304373"><span class="h3">Laboratory tests</span><span class="headingEndMark"> — </span>Antibodies against the noncollagenous extracellular domain of BP180 known as NC16A (the primary site for antibody binding in bullous pemphigoid) can be detected in the serum by a commercially available ELISA assay (BP180 NC16A ELISA). This test is sensitive and specific for the diagnosis of pemphigoid gestationis, and its positivity can be considered diagnostic in patients with typical clinical features [<a href="#rid42">42,43</a>]. The sensitivity and specificity of BP180 NC16A ELISA test range from 96 to 100 percent [<a href="#rid42">42-44</a>].</p><p>The levels of circulating anti-BP180 antibodies correlate with disease severity and are useful to monitor the response to treatment. The anti-BP180 levels tend to remain elevated up to one year after pregnancy and may persist during subsequent pregnancies even in the absence of a new episode of pemphigoid gestationis [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H903422286"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of pemphigoid gestationis primarily includes polymorphic eruption of pregnancy (PEP), dermatitis herpetiformis, erythema multiforme, and allergic contact dermatitis.</p><p class="headingAnchor" id="H827637772"><span class="h3">Polymorphic eruption of pregnancy</span><span class="headingEndMark"> — </span>The early urticarial plaques of pemphigoid gestationis are clinically and histologically indistinguishable from PEP.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical criteria</strong> – A clinical clue to help differentiate the two disorders is that PEP often begins in the striae, while pemphigoid gestationis is truly periumbilical  (<a class="graphic graphic_table graphicRef110440" href="/z/d/graphic/110440.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1">A tool called the Pregnancy Dermatoses Clinical Scoring System (PDCSS) has been proposed to differentiate pemphigoid gestationis from PEP in settings with limited access to DIF or testing for specific circulating antibodies [<a href="#rid46">46</a>]. Elements of clinical history (ie, previous pemphigoid gestationis, primigravida, onset between 28 and 36 weeks, or onset before 28 weeks) and clinical findings (ie, umbilical involvement, rash in striae, bullae) are assigned a score ranging from -2 to +2. In a multicenter validation study that included 19 patients with pemphigoid gestationis and 39 with PEP, PDCSS was able to differentiate pemphigoid gestationis from PEP with a sensitivity of 79 percent and a specificity of 95 percent [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct immunofluorescence</strong> – DIF of perilesional skin showing linear C3 deposition along the dermoepidermal junction is pathognomonic of pemphigoid gestationis. In PEP, DIF is usually negative or may show a nonspecific, granular deposition of C3 at the dermoepidermal junction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Circulating antibodies</strong> – The demonstration of circulating antibodies against BP180 NC16A by ELISA test will confirm the diagnosis of pemphigoid gestationis. In PEP, BP180 NC16A antibodies are always negative. (See <a class="local">'Polymorphic eruption of pregnancy'</a> above.)</p><p></p><p class="headingAnchor" id="H1189419372"><span class="h3">Other skin eruptions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatitis herpetiformis</strong> – Dermatitis herpetiformis (DH) is a very pruritic, vesicular autoimmune skin eruption associated with gluten sensitivity. In contrast with pemphigoid gestationis, DH lesions are typically located on the elbows, dorsal forearms, knees, scalp, back, and buttocks  (<a class="graphic graphic_picture graphicRef86768 graphicRef86751" href="/z/d/graphic/86768.html" rel="external">picture 12A-B</a>). DIF of perilesional skin showing granular deposits of IgA within the dermal papillae confirms the diagnosis of DH. (See  <a class="medical medical_review" href="/z/d/html/15307.html" rel="external">"Dermatitis herpetiformis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema multiforme</strong> – Erythema multiforme, whether due to pregnancy, infection, or drugs, can mimic pemphigoid gestationis clinically, but routine histology usually distinguishes between these disorders. (See  <a class="medical medical_review" href="/z/d/html/5559.html" rel="external">"Erythema multiforme: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic contact dermatitis and drug reactions</strong> – Allergic contact dermatitis and drug reactions can also appear similar to pemphigoid gestationis on physical examination. Thus, a careful history regarding use of medications and exposure to environmental agents may be helpful for the correct diagnosis [<a href="#rid11">11,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/z/d/html/2089.html" rel="external">"Drug eruptions"</a>.)</p><p></p><p class="headingAnchor" id="H1619177901"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The main goals of treatment of pemphigoid gestationis are to decrease blister formation, promote the healing of blisters and erosions, and relieve pruritus. Due to its rarity, the therapies for pemphigoid gestationis have not been evaluated in randomized trials. Treatment is based upon clinical experience and evidence from studies on bullous pemphigoid [<a href="#rid47">47-49</a>]. (See  <a class="medical medical_review" href="/z/d/html/15297.html" rel="external">"Management and prognosis of bullous pemphigoid"</a>.)</p><p>We suggest high-potency topical corticosteroids (groups 2 and 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 4</a>)) for initial therapy of localized disease. Vehicles for topical corticosteroids  (<a class="graphic graphic_table graphicRef60921" href="/z/d/graphic/60921.html" rel="external">table 5B</a>) and doses are illustrated in the tables  (<a class="graphic graphic_table graphicRef76586 graphicRef60921" href="/z/d/graphic/76586.html" rel="external">table 5A-B</a>). Ointments tend to cause less stinging and may be more effective than other topical preparations but are more cumbersome. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Use during pregnancy or lactation'</a>.)</p><p>If symptoms are not controlled by topical corticosteroids, which is common, then systemic corticosteroids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg per day) are usually effective. Once the symptoms are stabilized, the dose may be tapered and even discontinued in some patients. However, reinstatement of treatment postpartum will likely be needed [<a href="#rid11">11,34</a>].</p><p>The use of systemic corticosteroids during the pregnancy appears to be relatively safe. Although early studies suggested an association between systemic corticosteroids and risk of miscarriage or congenital malformation (oral clefts), larger population-based studies have not confirmed these findings [<a href="#rid50">50,51</a>]. However, limited data suggest an increased risk of preterm birth or low birth weight for women with pemphigoid gestationis or other autoimmune diseases exposed to systemic corticosteroids during the pregnancy:</p><p class="bulletIndent1"><span class="glyph">●</span>A study of 61 women with pemphigoid gestationis found an increased risk of low birth weight for women treated with ≥60 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> per day, after adjusting for maternal age and comorbidities (odds ratio 16.65, 95% CI 1.15-241.46) [<a href="#rid7">7</a>]. However, because of the small sample size and wide confidence interval, the magnitude of the risk remains uncertain. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a nationwide Danish cohort study of 900 pregnant women with Crohn disease exposed to various treatments, 73 received systemic corticosteroids [<a href="#rid52">52</a>]. In this group, there were nine (12 percent) preterm births and one (1.4 percent) low birth weight at term.</p><p></p><p>Severe, persistent <strong>postpartum</strong> pemphigoid gestationis may require higher doses of systemic corticosteroids or alternative immunosuppressant agents. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> up to 2 mg/kg per day can be given until a clinical response is achieved and then tapered and maintained at the lowest effective dose. Alternative therapies that have been successfully used in a few patients with severe, persistent, postpartum pemphigoid gestationis include <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, high-dose intravenous immunoglobulins (2 g/kg per cycle) [<a href="#rid53">53-56</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid57">57</a>], <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid58">58</a>], <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">nicotinamide</a> [<a href="#rid59">59</a>], <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid60">60</a>], immunoapheresis [<a href="#rid61">61</a>], and <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid62">62</a>].</p><p>First-generation oral antihistamine <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">chlorpheniramine</a> or second-generation <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a> and <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a> may be helpful for the symptomatic control of pruritus. (See  <a class="medical medical_review" href="/z/d/html/5552.html" rel="external">"Recognition and management of allergic disease during pregnancy", section on 'Oral antihistamines'</a>.)</p><p class="headingAnchor" id="H3256925141"><span class="h2">Prognosis</span></p><p class="headingAnchor" id="H3573987379"><span class="h3">Fetal prognosis</span><span class="headingEndMark"> — </span>The fetal prognosis is generally good, despite an increased risk of prematurity and small-for-gestational-age babies due to mild placental failure [<a href="#rid7">7,63,64</a>]. There is no increased risk of miscarriage.</p><p>A few newborns present with blisters (neonatal pemphigoid gestationis), due to the transplacental passage of maternal IgG autoantibodies. The eruption has a mild course and resolves within weeks without treatment [<a href="#rid65">65-67</a>]. There is minimal risk of adrenal suppression in the newborn, even if the mother has been maintained on high-dose corticosteroids.</p><p class="headingAnchor" id="H1702818999"><span class="h3">Maternal prognosis</span><span class="headingEndMark"> — </span>The mother is at high risk of recurrent pemphigoid gestationis with subsequent pregnancies.</p><p class="headingAnchor" id="H1323469443"><span class="h1">INTRAHEPATIC CHOLESTASIS OF PREGNANCY</span><span class="headingEndMark"> — </span>Intrahepatic cholestasis of pregnancy (ICP; obstetric cholestasis) is the only pregnancy dermatosis without primary skin changes [<a href="#rid68">68</a>]. Patients experience severe, generalized pruritus, predominantly on the palms and soles, and may present with excoriations secondary to scratching.</p><p>ICP carries significant morbidity for the fetus, including prematurity, meconium-stained amniotic fluid, intrauterine demise, and an increased risk for neonatal respiratory distress syndrome. The maternal prognosis is generally favorable, although one study suggests that affected women have an increased risk of later hepatobiliary disease [<a href="#rid69">69</a>].</p><p>The pathogenesis, clinical manifestations, diagnosis, and treatment of ICP are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a>.)</p><p class="headingAnchor" id="H52"><span class="h1">PUSTULAR PSORIASIS OF PREGNANCY</span><span class="headingEndMark"> — </span>Pustular psoriasis of pregnancy (PPP), formerly called impetigo herpetiformis, is an exceedingly rare variant of generalized pustular psoriasis occurring during pregnancy or triggered by pregnancy [<a href="#rid70">70</a>]. It typically presents during the third trimester but may occur earlier or in the immediate postpartum period. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/93554.html" rel="external">"Pustular psoriasis: Management"</a>.)</p><p class="headingAnchor" id="H54"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>PPP can occur anytime during pregnancy but typically presents in the third trimester of pregnancy with symmetric, erythematous plaques studded at the periphery with sterile pustules in a circinate pattern  (<a class="graphic graphic_picture graphicRef110694" href="/z/d/graphic/110694.html" rel="external">picture 4</a>) [<a href="#rid4">4</a>]. The plaques then enlarge from the periphery as the center becomes eroded and crusted  (<a class="graphic graphic_picture graphicRef56769" href="/z/d/graphic/56769.html" rel="external">picture 13B</a>). There may be concentric rings of pustules. The pustules are typically sterile.</p><p>The eruption begins in the flexural areas and spreads centrifugally. The trunk and extremities are usually involved, while the hands, feet, and face are usually spared. Oral and esophageal erosions may occur. The nails may become onycholytic (lifting of the nail plate from the nail bed) [<a href="#rid71">71,72</a>]; pitting has also been described [<a href="#rid73">73</a>].</p><p>Pruritus is usually absent. Systemic symptoms are severe and include malaise, fever, anorexia, nausea, vomiting, diarrhea, and tetany [<a href="#rid71">71,72</a>].</p><p>Leukocytosis and elevated erythrocyte sedimentation rate are common. Hypocalcemia may be present, possibly related to hypoparathyroidism [<a href="#rid71">71</a>] and can lead to tetany, delirium, and seizures. Albuminuria, hypoalbuminemia, pyuria, and hematuria occasionally occur.</p><p class="headingAnchor" id="H1243137981"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis can be made clinically, based upon history and physical examination  (<a class="graphic graphic_picture graphicRef79167 graphicRef56769" href="/z/d/graphic/79167.html" rel="external">picture 13A-B</a>). However, we suggest confirmation by histologic evaluation of a biopsy specimen, given the potential consequences of the disease and its treatment to maternal and child health (eg, side effects of systemic corticosteroids, preterm delivery).</p><p class="headingAnchor" id="H57"><span class="h3">Pathology</span><span class="headingEndMark"> — </span>The histopathologic features of PPP are the same as those of pustular psoriasis in the nonpregnant patient. Spongiform pustules with neutrophils are observed in the epidermis. Psoriasiform hyperplasia and parakeratosis also occur [<a href="#rid71">71,72</a>]. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Histopathology'</a>.)</p><p class="headingAnchor" id="H1150877896"><span class="h3">Laboratory tests</span><span class="headingEndMark"> — </span>The initial laboratory evaluation includes a complete blood count with differential and a complete metabolic panel to evaluate for hypocalcemia, other electrolyte abnormalities, hypoalbuminemia, and liver and renal function. Pustule cultures for bacteria or yeasts may be obtained.</p><p class="headingAnchor" id="H59"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>An infectious etiology for the pustular eruption (eg, candidiasis, tinea corporis, impetigo) should be excluded by appropriate cultures. Other dermatoses that should be considered in the differential diagnosis of PPP include:</p><p class="bulletIndent1"><span class="glyph">●</span>Subcorneal pustular dermatosis  (<a class="graphic graphic_picture graphicRef71995" href="/z/d/graphic/71995.html" rel="external">picture 14</a>) can mimic PPP clinically and histopathologically but is typically asymptomatic. The presence of severe systemic symptoms suggests PPP. (See  <a class="medical medical_review" href="/z/d/html/99482.html" rel="external">"Subcorneal pustular dermatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute generalized exanthematous pustulosis (AGEP)  (<a class="graphic graphic_picture graphicRef56807" href="/z/d/graphic/56807.html" rel="external">picture 15</a>) is a severe drug reaction that typically manifests with the rapid development of dozens to hundreds of nonfollicular, sterile, pinhead-sized pustules that usually occurs a few hours to a few days after exposure to an offending drug, most often an antibiotic. The absence of a history of drug exposure helps in distinguishing PPP from AGEP. (See  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritic folliculitis of pregnancy is pruritic and exclusively perifollicular, neither of which is true of PPP. (See <a class="local">'Pruritic folliculitis of pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pemphigoid gestationis can present with rings of vesicles or pustules, but histopathology is different. (See <a class="local">'Pemphigoid gestationis'</a> above.)</p><p></p><p class="headingAnchor" id="H60"><span class="h2">Management</span><span class="headingEndMark"> — </span>Because of the associated risk for the fetus, prompt institution of treatment is required for women with PPP. Fetal monitoring with nonstress tests or biophysical profiles and ultrasound assessment of fetal growth are indicated. Hypocalcemia must be corrected, when present, and fluid and electrolyte balance should be maintained. These patients sometimes require early delivery for relief of symptoms and for fetal safety [<a href="#rid71">71,72,74</a>].</p><p>Evidence for the treatment of PPP is limited [<a href="#rid75">75</a>]. We suggest systemic corticosteroids as initial therapy. High-dose systemic corticosteroids, such as <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> up to 60 to 80 mg per day, are given for a few days and then slowly tapered as symptoms improve, with monitoring in case a flare occurs.</p><p>Low-dose <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (2 to 3 mg/kg per day) may be an alternative to systemic corticosteroids for patients with PPP [<a href="#rid75">75-79</a>]. Data from studies in pregnant patients with organ transplantation indicate that the risk of teratogenicity is low, but premature labor and infants small for gestational age have been reported. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p>There are isolated reports of successful use of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid80">80,81</a>]. In a review from the medical board of the National Psoriasis Foundation, corticosteroids, cyclosporin, and infliximab were all listed as first-line treatments [<a href="#rid75">75</a>]. For persistent cases, after delivery and in mothers who are not breastfeeding, systemic retinoids or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are additional therapeutic options [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/5663.html" rel="external">"Management of psoriasis in pregnancy"</a>.)</p><p class="headingAnchor" id="H61"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>PPP usually remits quickly postpartum but may flare after delivery [<a href="#rid73">73,82,83</a>]. Placental insufficiency with severe sequelae such as miscarriage, fetal growth restriction, or stillbirth may occur [<a href="#rid84">84,85</a>].</p><p class="headingAnchor" id="H3458964678"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119371.html" rel="external">"Society guideline links: Dermatoses of pregnancy"</a>.)</p><p class="headingAnchor" id="H64"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and clinical features</strong> – The dermatoses of pregnancy are a heterogeneous group of pruritic inflammatory dermatoses that occur exclusively during pregnancy and/or in the immediate postpartum period. They include pemphigoid gestationis  (<a class="graphic graphic_picture graphicRef134253 graphicRef72690 graphicRef52776" href="/z/d/graphic/134253.html" rel="external">picture 10A-C</a>), polymorphic eruption of pregnancy (PEP)  (<a class="graphic graphic_picture graphicRef56116 graphicRef75861" href="/z/d/graphic/56116.html" rel="external">picture 6A-B</a>), previously known as pruritic urticarial papules and plaques of pregnancy (PUPPP), atopic eruption of pregnancy (AEP)  (<a class="graphic graphic_picture graphicRef72147" href="/z/d/graphic/72147.html" rel="external">picture 2</a>), intrahepatic cholestasis of pregnancy (ICP), and pustular psoriasis of pregnancy (PPP)  (<a class="graphic graphic_picture graphicRef110694" href="/z/d/graphic/110694.html" rel="external">picture 4</a>). The time of onset and relevant clinical features are summarized in the table  (<a class="graphic graphic_table graphicRef110440" href="/z/d/graphic/110440.html" rel="external">table 3</a>). (See <a class="local">'Atopic eruption of pregnancy'</a> above and <a class="local">'Polymorphic eruption of pregnancy'</a> above and <a class="local">'Pemphigoid gestationis'</a> above and <a class="local">'Intrahepatic cholestasis of pregnancy'</a> above and <a class="local">'Pustular psoriasis of pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis </strong>– A pregnant individual with a pruritic skin eruption requires immediate evaluation and diagnosis because delayed diagnosis or misdiagnosis may pose a significant risk to the fetus and the mother. The initial assessment is summarized in the table  (<a class="graphic graphic_table graphicRef69237" href="/z/d/graphic/69237.html" rel="external">table 2</a>) (see <a class="local">'Evaluation of the pregnant individual with a pruritic eruption'</a> above and <a class="local">'When to suspect a specific dermatosis of pregnancy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PEP and AEP, including prurigo of pregnancy and pruritic folliculitis of pregnancy, can be diagnosed clinically, based upon characteristic findings on history and physical examination alone. Bile acids should be checked in patients with extensive pruritus and no primary skin lesions. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Intrahepatic cholestasis of pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients suspected to have pemphigoid gestationis or pustular psoriasis should undergo skin biopsy with histopathologic assessment, direct immunofluorescence (DIF) test, and measurement of circulating antibodies against BP180 NC16A to confirm the clinical diagnosis. (See <a class="local">'Pemphigoid gestationis'</a> above and <a class="local">'Pustular psoriasis of pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment recommendations depend on the specific disorder:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atopic eruption of pregnancy</strong> – For patients with AEP, we suggest low- to mid-potency corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients should be encouraged to maintain adequate skin hydration through the frequent use of emollients. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pemphigoid gestationis</strong> – For patients with pemphigoid gestationis, we suggest high-potency (group 2 and 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 4</a>)) topical corticosteroid ointments as initial treatment for localized disease (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We administer oral corticosteroids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg per day) if the symptoms are not controlled by topical therapy. Higher doses of oral corticosteroids or other systemic immunosuppressive agents may be needed in patients with severe persistent postpartum pemphigoid gestationis. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Polymorphic eruption of pregnancy</strong> – For patients with PEP, prurigo of pregnancy, and pruritic folliculitis of pregnancy, we suggest low- to medium-potency (group 4 to 6  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 4</a>)) topical corticosteroid ointments (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Oral antihistamines may be helpful for the symptomatic treatment of pruritus. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/5552.html" rel="external">"Recognition and management of allergic disease during pregnancy", section on 'Oral antihistamines'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intrahepatic cholestasis</strong> – The management of ICP is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy", section on 'Maternal treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pustular psoriasis</strong> – Pustular psoriasis is treated with high-dose oral corticosteroids (up to 60 to 80 mg per day). Low-dose <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (2 to 3 mg/kg per day) and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> are other treatment options, especially for patients who fail to respond to corticosteroids. Patients should be evaluated for hypocalcemia, which can be symptomatic. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/z/d/html/5663.html" rel="external">"Management of psoriasis in pregnancy"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ambros-Rudolph CM. Dermatoses of pregnancy - clues to diagnosis, fetal risk and therapy. Ann Dermatol 2011; 23:265.</a></li><li><a class="nounderline abstract_t">Vaughan Jones SA, Hern S, Nelson-Piercy C, et al. A prospective study of 200 women with dermatoses of pregnancy correlating clinical findings with hormonal and immunopathological profiles. Br J Dermatol 1999; 141:71.</a></li><li><a class="nounderline abstract_t">Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, et al. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54:395.</a></li><li><a class="nounderline abstract_t">Lehrhoff S, Pomeranz MK. Specific dermatoses of pregnancy and their treatment. Dermatol Ther 2013; 26:274.</a></li><li><a class="nounderline abstract_t">Vaughan Jones S, Ambros-Rudolph C, Nelson-Piercy C. Skin disease in pregnancy. BMJ 2014; 348:g3489.</a></li><li><a class="nounderline abstract_t">Massone C, Cerroni L, Heidrun N, et al. Histopathological diagnosis of atopic eruption of pregnancy and polymorphic eruption of pregnancy: a study on 41 cases. Am J Dermatopathol 2014; 36:812.</a></li><li><a class="nounderline abstract_t">Chi CC, Wang SH, Charles-Holmes R, et al. Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes. Br J Dermatol 2009; 160:1222.</a></li><li><a class="nounderline abstract_t">Roth MM, Cristodor P, Kroumpouzos G. Prurigo, pruritic folliculitis, and atopic eruption of pregnancy: Facts and controversies. Clin Dermatol 2016; 34:392.</a></li><li><a class="nounderline abstract_t">Wilder RL. Hormones, pregnancy, and autoimmune diseases. Ann N Y Acad Sci 1998; 840:45.</a></li><li><a class="nounderline abstract_t">Roger D, Vaillant L, Fignon A, et al. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. Arch Dermatol 1994; 130:734.</a></li><li><a class="nounderline abstract_t">Shornick JK. Dermatoses of pregnancy. Semin Cutan Med Surg 1998; 17:172.</a></li><li><a class="nounderline abstract_t">Holmes RC, Black MM. The specific dermatoses of pregnancy. J Am Acad Dermatol 1983; 8:405.</a></li><li><a class="nounderline abstract_t">Nurse DS. Prurigo of pregnancy. Australas J Dermatol 1968; 9:258.</a></li><li><a class="nounderline abstract_t">Kroumpouzos G, Cohen LM. Pruritic folliculitis of pregnancy. J Am Acad Dermatol 2000; 43:132.</a></li><li><a class="nounderline abstract_t">Vaughan Jones SA, Black MM. Pregnancy dermatoses. J Am Acad Dermatol 1999; 40:233.</a></li><li><a class="nounderline abstract_t">Zoberman E, Farmer ER. Pruritic folliculitis of pregnancy. Arch Dermatol 1981; 117:20.</a></li><li><a class="nounderline abstract_t">Taylor D, Pappo E, Aronson IK. Polymorphic eruption of pregnancy. Clin Dermatol 2016; 34:383.</a></li><li><a class="nounderline abstract_t">Aronson IK, Bond S, Fiedler VC, et al. Pruritic urticarial papules and plaques of pregnancy: clinical and immunopathologic observations in 57 patients. J Am Acad Dermatol 1998; 39:933.</a></li><li><a class="nounderline abstract_t">Alcalay J, Ingber A, Hazaz B, et al. Linear IgM dermatosis of pregnancy. J Am Acad Dermatol 1988; 18:412.</a></li><li><a class="nounderline abstract_t">Cohen LM, Capeless EL, Krusinski PA, Maloney ME. Pruritic urticarial papules and plaques of pregnancy and its relationship to maternal-fetal weight gain and twin pregnancy. Arch Dermatol 1989; 125:1534.</a></li><li><a class="nounderline abstract_t">Elling SV, McKenna P, Powell FC. Pruritic urticarial papules and plaques of pregnancy in twin and triplet pregnancies. J Eur Acad Dermatol Venereol 2000; 14:378.</a></li><li><a class="nounderline abstract_t">Kroumpouzos G, Cohen LM. Specific dermatoses of pregnancy: an evidence-based systematic review. Am J Obstet Gynecol 2003; 188:1083.</a></li><li><a class="nounderline abstract_t">Beckett MA, Goldberg NS. Pruritic urticarial plaques and papules of pregnancy and skin distention. Arch Dermatol 1991; 127:125.</a></li><li><a class="nounderline abstract_t">Aractingi S, Berkane N, Bertheau P, et al. Fetal DNA in skin of polymorphic eruptions of pregnancy. Lancet 1998; 352:1898.</a></li><li><a class="nounderline abstract_t">Yancey KB, Hall RP, Lawley TJ. Pruritic urticarial papules and plaques of pregnancy. Clinical experience in twenty-five patients. J Am Acad Dermatol 1984; 10:473.</a></li><li><a class="nounderline abstract_t">Regnier S, Fermand V, Levy P, et al. A case-control study of polymorphic eruption of pregnancy. J Am Acad Dermatol 2008; 58:63.</a></li><li><a class="nounderline abstract_t">Lawley TJ, Hertz KC, Wade TR, et al. Pruritic urticarial papules and plaques of pregnancy. JAMA 1979; 241:1696.</a></li><li><a class="nounderline abstract_t">Rudolph CM, Al-Fares S, Vaughan-Jones SA, et al. Polymorphic eruption of pregnancy: clinicopathology and potential trigger factors in 181 patients. Br J Dermatol 2006; 154:54.</a></li><li><a class="nounderline abstract_t">Chi CC, Wang SH, Kirtschig G. Safety of Topical Corticosteroids in Pregnancy. JAMA Dermatol 2016; 152:934.</a></li><li><a class="nounderline abstract_t">Chi CC, Wang SH, Wojnarowska F, et al. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev 2015; :CD007346.</a></li><li><a class="nounderline abstract_t">Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol 2013; 149:1274.</a></li><li><a class="nounderline abstract_t">Beltrani VP, Beltrani VS. Pruritic urticarial papules and plaques of pregnancy: a severe case requiring early delivery for relief of symptoms. J Am Acad Dermatol 1992; 26:266.</a></li><li><a class="nounderline abstract_t">Huilaja L, Mäkikallio K, Tasanen K. Gestational pemphigoid. Orphanet J Rare Dis 2014; 9:136.</a></li><li class="breakAll">Katz SI. Herpes gestationis (pemphigoid gestationis). In: Fitzpatrick's Dermatology in General Medicine, 5th ed, Freedberg I, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, 1999. p.686.</li><li><a class="nounderline abstract_t">Jenkins RE, Hern S, Black MM. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Exp Dermatol 1999; 24:255.</a></li><li><a class="nounderline abstract_t">Jenkins RE, Jones SA, Black MM. Conversion of pemphigoid gestationis to bullous pemphigoid--two refractory cases highlighting this association. Br J Dermatol 1996; 135:595.</a></li><li><a class="nounderline abstract_t">Di Zenzo G, Calabresi V, Grosso F, et al. The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. J Invest Dermatol 2007; 127:864.</a></li><li><a class="nounderline abstract_t">Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity 2012; 45:55.</a></li><li><a class="nounderline abstract_t">Sadik CD, Lima AL, Zillikens D. Pemphigoid gestationis: Toward a better understanding of the etiopathogenesis. Clin Dermatol 2016; 34:378.</a></li><li><a class="nounderline abstract_t">García-González E, Castro-Llamas J, Karchmer S, et al. Class II major histocompatibility complex typing across the ethnic barrier in pemphigoid gestationis. A study in Mexicans. Int J Dermatol 1999; 38:46.</a></li><li><a class="nounderline abstract_t">Shornick JK, Jenkins RE, Artlett CM, et al. Class II MHC typing in pemphigoid gestationis. Clin Exp Dermatol 1995; 20:123.</a></li><li><a class="nounderline abstract_t">Powell AM, Sakuma-Oyama Y, Oyama N, et al. Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy. Arch Dermatol 2005; 141:705.</a></li><li><a class="nounderline abstract_t">Al Saif F, Jouen F, Hebert V, et al. Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. J Am Acad Dermatol 2017; 76:560.</a></li><li><a class="nounderline abstract_t">Sitaru C, Dähnrich C, Probst C, et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16:770.</a></li><li><a class="nounderline abstract_t">Huilaja L, Surcel HM, Bloigu A, Tasanen K. Elevated serum levels of BP180 antibodies in the first trimester of pregnancy precede gestational pemphigoid and remain elevated for a long time after remission of the disease. Acta Derm Venereol 2015; 95:843.</a></li><li><a class="nounderline abstract_t">Xie F, Davis DMR, Baban F, et al. Development and multicenter international validation of a diagnostic tool to differentiate between pemphigoid gestationis and polymorphic eruption of pregnancy. J Am Acad Dermatol 2023; 89:106.</a></li><li><a class="nounderline abstract_t">Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346:321.</a></li><li><a class="nounderline abstract_t">Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129:1681.</a></li><li><a class="nounderline abstract_t">Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; :CD002292.</a></li><li><a class="nounderline abstract_t">Bjørn AM, Nielsen RB, Nørgaard M, et al. Risk of miscarriage among users of corticosteroid hormones: a population-based nested case-control study. Clin Epidemiol 2013; 5:287.</a></li><li><a class="nounderline abstract_t">Bay Bjørn AM, Ehrenstein V, Hundborg HH, et al. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther 2014; 21:73.</a></li><li><a class="nounderline abstract_t">Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102:1406.</a></li><li><a class="nounderline abstract_t">Gan DC, Welsh B, Webster M. Successful treatment of a severe persistent case of pemphigoid gestationis with antepartum and postpartum intravenous immunoglobulin followed by azathioprine. Australas J Dermatol 2012; 53:66.</a></li><li><a class="nounderline abstract_t">Rodrigues Cdos S, Filipe P, Solana Mdel M, et al. Persistent herpes gestationis treated with high-dose intravenous immunoglobulin. Acta Derm Venereol 2007; 87:184.</a></li><li><a class="nounderline abstract_t">Nguyen T, Alraqum E, Razzaque Ahmed A. Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis. Int Immunopharmacol 2015; 26:1.</a></li><li><a class="nounderline abstract_t">Doiron P, Pratt M. Antepartum intravenous immunoglobulin therapy in refractory pemphigoid gestationis: case report and literature review. J Cutan Med Surg 2010; 14:189.</a></li><li><a class="nounderline abstract_t">Huilaja L, Mäkikallio K, Hannula-Jouppi K, et al. Cyclosporine treatment in severe gestational pemphigoid. Acta Derm Venereol 2015; 95:593.</a></li><li><a class="nounderline abstract_t">Castle SP, Mather-Mondrey M, Bennion S, et al. Chronic herpes gestationis and antiphospholipid antibody syndrome successfully treated with cyclophosphamide. J Am Acad Dermatol 1996; 34:333.</a></li><li><a class="nounderline abstract_t">Amato L, Coronella G, Berti S, et al. Successful treatment with doxycycline and nicotinamide of two cases of persistent pemphigoid gestationis. J Dermatolog Treat 2002; 13:143.</a></li><li><a class="nounderline abstract_t">Cianchini G, Masini C, Lupi F, et al. Severe persistent pemphigoid gestationis: long-term remission with rituximab. Br J Dermatol 2007; 157:388.</a></li><li><a class="nounderline abstract_t">Marker M, Derfler K, Monshi B, Rappersberger K. Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. J Dtsch Dermatol Ges 2011; 9:27.</a></li><li><a class="nounderline abstract_t">Konstantinou MP, Jendoubi F, Fortenfant F, et al. Successful treatment of recalcitrant pemphigoid gestationis with omalizumab: report of two cases. J Eur Acad Dermatol Venereol 2022; 36:e720.</a></li><li><a class="nounderline abstract_t">Shornick JK, Black MM. Fetal risks in herpes gestationis. J Am Acad Dermatol 1992; 26:63.</a></li><li><a class="nounderline abstract_t">Al-Saif F, Elisa A, Al-Homidy A, et al. Retrospective analysis of pemphigoid gestationis in 32 Saudi patients - Clinicopathological features and a literature review. J Reprod Immunol 2016; 116:42.</a></li><li><a class="nounderline abstract_t">Aoyama Y, Asai K, Hioki K, et al. Herpes gestationis in a mother and newborn: immunoclinical perspectives based on a weekly follow-up of the enzyme-linked immunosorbent assay index of a bullous pemphigoid antigen noncollagenous domain. Arch Dermatol 2007; 143:1168.</a></li><li><a class="nounderline abstract_t">Chorzelski TP, Jablonska S, Beutner EH, et al. Herpes gestations with identical lesions in the newborn. Passive transfer of the disease? Arch Dermatol 1976; 112:1129.</a></li><li><a class="nounderline abstract_t">Katz A, Minto JO, Toole JW, Medwidsky W. Immunopathologic study of herpes gestationis in mother and infant. Arch Dermatol 1977; 113:1069.</a></li><li><a class="nounderline abstract_t">Hillman SC, Stokes-Lampard H, Kilby MD. Intrahepatic cholestasis of pregnancy. BMJ 2016; 353:i1236.</a></li><li><a class="nounderline abstract_t">Marschall HU, Wikström Shemer E, Ludvigsson JF, Stephansson O. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. Hepatology 2013; 58:1385.</a></li><li><a class="nounderline abstract_t">Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J Womens Health 2018; 10:109.</a></li><li class="breakAll">Bellman B, Berman B. Skin diseases seriously affecting fetal outcome and matemal health. In: Skin Changes and Diseases in Pregnancy, Harahap M, Wallach RC (Eds), Marcel Dekker, Inc, 1996. p.129.</li><li class="breakAll">Charles-Holmes R. Skin diseases specifically associated with pregnancy. In: Skin Changes and Diseases in Pregnancy, Harahap M, Wallach RC (Eds), Marcel Dekker, Inc, 1996. p.55.</li><li><a class="nounderline abstract_t">Breier-Maly J, Ortel B, Breier F, et al. Generalized pustular psoriasis of pregnancy (impetigo herpetiformis). Dermatology 1999; 198:61.</a></li><li><a class="nounderline abstract_t">Henson TH, Tuli M, Bushore D, Talanin NY. Recurrent pustular rash in a pregnant woman. Arch Dermatol 2000; 136:1055.</a></li><li><a class="nounderline abstract_t">Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012; 67:279.</a></li><li><a class="nounderline abstract_t">Hazarika D. Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine. Indian J Dermatol Venereol Leprol 2009; 75:638.</a></li><li><a class="nounderline abstract_t">Kapoor R, Kapoor JR. Cyclosporine resolves generalized pustular psoriasis of pregnancy. Arch Dermatol 2006; 142:1373.</a></li><li><a class="nounderline abstract_t">Shaw CJ, Wu P, Sriemevan A. First trimester impetigo herpetiformis in multiparous female successfully treated with oral cyclosporine. BMJ Case Rep 2011; 2011.</a></li><li><a class="nounderline abstract_t">Patsatsi A, Theodoridis TD, Vavilis D, et al. Cyclosporine in the management of impetigo herpetiformis: a case report and review of the literature. Case Rep Dermatol 2013; 5:99.</a></li><li><a class="nounderline abstract_t">Sheth N, Greenblatt DT, Acland K, et al. Generalized pustular psoriasis of pregnancy treated with infliximab. Clin Exp Dermatol 2009; 34:521.</a></li><li><a class="nounderline abstract_t">Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology 2010; 220:71.</a></li><li><a class="nounderline abstract_t">Arslanpence I, Dede FS, Gokcu M, Gelisen O. Impetigo herpetiformis unresponsive to therapy in a pregnant adolescent. J Pediatr Adolesc Gynecol 2003; 16:129.</a></li><li><a class="nounderline abstract_t">Katsambas A, Stavropoulos PG, Katsiboulas V, et al. Impetigo herpetiformis during the puerperium. Dermatology 1999; 198:400.</a></li><li><a class="nounderline abstract_t">Bukhari IA. Impetigo herpetiformis in a primigravida: successful treatment with etretinate. J Drugs Dermatol 2004; 3:449.</a></li><li><a class="nounderline abstract_t">Oumeish OY, Parish JL. Impetigo herpetiformis. Clin Dermatol 2006; 24:101.</a></li></ol></div><div id="topicVersionRevision">Topic 5564 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21909194" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dermatoses of pregnancy - clues to diagnosis, fetal risk and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10417518" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A prospective study of 200 women with dermatoses of pregnancy correlating clinical findings with hormonal and immunopathological profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488288" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23914884" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Specific dermatoses of pregnancy and their treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24895225" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Skin disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25243396" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Histopathological diagnosis of atopic eruption of pregnancy and polymorphic eruption of pregnancy: a study on 41 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19298272" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265078" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prurigo, pruritic folliculitis, and atopic eruption of pregnancy: Facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9629235" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hormones, pregnancy, and autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8002643" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9759674" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dermatoses of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6833540" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The specific dermatoses of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5673933" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prurigo of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10863240" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pruritic folliculitis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025751" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pregnancy dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7458373" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pruritic folliculitis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265077" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Polymorphic eruption of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843004" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pruritic urticarial papules and plaques of pregnancy: clinical and immunopathologic observations in 57 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3278020" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Linear IgM dermatosis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2817917" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pruritic urticarial papules and plaques of pregnancy and its relationship to maternal-fetal weight gain and twin pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11305379" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pruritic urticarial papules and plaques of pregnancy in twin and triplet pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712115" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Specific dermatoses of pregnancy: an evidence-based systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1986699" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pruritic urticarial plaques and papules of pregnancy and skin distention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9863788" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fetal DNA in skin of polymorphic eruptions of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6725659" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pruritic urticarial papules and plaques of pregnancy. Clinical experience in twenty-five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17884242" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A case-control study of polymorphic eruption of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/430731" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pruritic urticarial papules and plaques of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403094" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Polymorphic eruption of pregnancy: clinicopathology and potential trigger factors in 181 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27366995" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety of Topical Corticosteroids in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26497573" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety of topical corticosteroids in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24005903" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552069" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pruritic urticarial papules and plaques of pregnancy: a severe case requiring early delivery for relief of symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178359" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Gestational pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178359" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gestational pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10457123" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical features and management of 87 patients with pemphigoid gestationis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915153" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Conversion of pemphigoid gestationis to bullous pemphigoid--two refractory cases highlighting this association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17068480" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21923615" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pemphigoid diseases: pathogenesis, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265076" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pemphigoid gestationis: Toward a better understanding of the etiopathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10065610" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Class II major histocompatibility complex typing across the ethnic barrier in pemphigoid gestationis. A study in Mexicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565245" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Class II MHC typing in pemphigoid gestationis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967916" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28212762" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17697150" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25758329" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Elevated serum levels of BP180 antibodies in the first trimester of pregnancy precede gestational pemphigoid and remain elevated for a long time after remission of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36739091" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Development and multicenter international validation of a diagnostic tool to differentiate between pemphigoid gestationis and polymorphic eruption of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821508" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19177141" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927731" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Interventions for bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23983489" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risk of miscarriage among users of corticosteroid hormones: a population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23011170" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437503" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309336" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Successful treatment of a severe persistent case of pemphigoid gestationis with antepartum and postpartum intravenous immunoglobulin followed by azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17340036" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Persistent herpes gestationis treated with high-dose intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25765353" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20642990" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antepartum intravenous immunoglobulin therapy in refractory pemphigoid gestationis: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519774" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cyclosporine treatment in severe gestational pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8655721" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Chronic herpes gestationis and antiphospholipid antibody syndrome successfully treated with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12227878" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Successful treatment with doxycycline and nicotinamide of two cases of persistent pemphigoid gestationis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17553047" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Severe persistent pemphigoid gestationis: long-term remission with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20812992" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35592910" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Successful treatment of recalcitrant pemphigoid gestationis with omalizumab: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732338" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fetal risks in herpes gestationis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27175516" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Retrospective analysis of pemphigoid gestationis in 32 Saudi patients - Clinicopathological features and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17875879" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Herpes gestationis in a mother and newborn: immunoclinical perspectives based on a weekly follow-up of the enzyme-linked immunosorbent assay index of a bullous pemphigoid antigen noncollagenous domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/782371" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Herpes gestations with identical lesions in the newborn. Passive transfer of the disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/329771" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Immunopathologic study of herpes gestationis in mother and infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27103313" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intrahepatic cholestasis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23564560" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29520163" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pustular psoriasis of pregnancy: current perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29520163" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pustular psoriasis of pregnancy: current perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29520163" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pustular psoriasis of pregnancy: current perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10026404" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Generalized pustular psoriasis of pregnancy (impetigo herpetiformis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926744" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Recurrent pustular rash in a pregnant woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22609220" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915261" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043209" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cyclosporine resolves generalized pustular psoriasis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696729" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : First trimester impetigo herpetiformis in multiparous female successfully treated with oral cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23626548" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cyclosporine in the management of impetigo herpetiformis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196309" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Generalized pustular psoriasis of pregnancy treated with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940453" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12804935" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Impetigo herpetiformis unresponsive to therapy in a pregnant adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449943" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Impetigo herpetiformis during the puerperium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15303793" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Impetigo herpetiformis in a primigravida: successful treatment with etretinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487882" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Impetigo herpetiformis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
